## AMENDMENT TO THE CONTENT OF PRICE INQUIRY NO. NUSI/58/PR45939/2024 as of 30.01.2024.

**Subject:** Project entitled "Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Agency for Medical Research, Warszawskie Zakłady Farmaceutyczne Polfa S.A.,

Subject of purchase - for purchase and delivery of RNA oligonucleotide standards.

The ordering party informs that on 30.01.2024 it changed the content of the price inquiry in the following scope:

Description before amendment			Description as amended		
III. DESCRIPTION OF THE SUBJECT OF THE PRICE INQUIRY					
3.1. quant	The subject of the Price Inquiry is the purchase and delivery of the following antities of the product:		<b>3.1.</b> The subject of the Price Inquiry is the purchase and delivery of the following quantities of the product:		
3	Oligonukleotide standard "error sequence 2" purity LCUV>85% with sequence 5'- G*MeU*A*MeC*MeU*MeC*A*MeU*A*A*MeU*G* MeC*MeU*G*MeU-3' * thiophosphate bonds; MeC, MeU - all C and U substituted 5'-methyl All 2'-O ribose substituted with methoxyethyl-; molecular formula: C234H340N61O128P17S17	3	Oligonucleotide standard "error sequence 1" LCUV purity >85% with sequence 5'-G*MeC*A*MeC*MeU*MeU*MeC*A*MeU* A*A*MeU*G*MeC*MeU*G*MeU-3' *thiophosphate bonds; MeC, MeU - all C and U substituted 5'-methyl  All 2'-O ribose substituted with methoxyethyl-; molecular formula:  C234H340N61O128P17S17	20mg	

Description before amendment	Description as amended			
VIII. PLACE AND DATES FOR SUBMITTING AND OPENING BIDS				
<ul> <li>8.1. The final deadline for submitting bids is 02.02.2024.</li> <li>- bids can be sent in electronic format as scanned documents to the following address: <a href="mailto:barbara.wendolowska@polpharma.com">barbara.wendolowska@polpharma.com</a></li> </ul>	8.1. The final deadline for submitting bids is 07.02.2024.  - bids can be sent in electronic format as scanned documents to the following address: barbara.wendolowska@polpharma.com			